Overview

Acute Treatment Trial in Adult Subjects With Migraines

Status:
Completed
Trial end date:
2019-11-11
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of three different intranasal dose levels of BHV-3500, relative to placebo, in the acute treatment of moderate to severe migraine.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.